NF Researchers

University of Wisconsin-Madison

Overview

Need to have some text about the importance of research and how the NF Network supports ongoing research in to a cure for NF.

Project Dream

The NF Network Research Program, “Project Dream”, under the leadership of the Scientific Advisory Committee (SAC), provides guidance and over- sight for funding research. We seek proposals to promote novel scientific inquiry in neurofibromatosis and schwannomatosis. Grants are typically awarded for 1 to 2 year periods, covering direct costs up to $50,000 per year. The SAC may, in some cases, recommend a grant to supplement funding from another source.

Check here for the Project Dream Application Process

Research Funding Announcement

Scientific Advisory Committee

Some text about the advisory committee

Frank Buono, PhD

Member at Large
Dr. Frank Buono is an Associate Research Scientist in Psychiatry at Yale School of Medicine. As an individual personally affected by NF2, Dr. Buono is conducting research focused on the NF population and its connection to pain.

Justin T. Jordan, MD, MPH Neurology

Chair of the NF Network Research Program
Dr. Jordan’s clinical interests are in primary nervous system tumors and in neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. His research interests are in the genetics of tumor development within these tumor predisposition syndromes, as well as therapeutic clinical trials for malignant brain tumors. He is also involved in clinical process improvement for brain tumor care at MGH, and contributes to patient care quality measurement development within the American Academy of Neurology and the Society for Neuro-Oncology.

Network Edge

The Neurofibromatosis Network and Neurofibromatosis Northeast are delighted to bring you our science column, The Network Edge, written by science writer Vanessa L. Merker, PhD, providing a summary of recent highlights from NF research and clinical trials.  The Network, through advocacy on Capitol Hill and direct funding of research, plays a central role in progress toward a cure.

Twice a year The Network Edge will bring you the latest research news as compiled by science writer, Vanessa L. Merker, PhD.  The goal is to keep you abreast of advancements in treatment and clinical care for all forms of NF.
 
The Network Edge is presented in bite-sized pieces, allowing you to easily find and focus on those topics of most interest to you, whether it is NF1 learning disabilities studies, NF2 clinical trial updates or schwannomatosis news.

Need Some type of Text about learning more

Learn More

NF Registry

The NF Registry, the patient-driven resource for accelerating research and finding treatments for all forms of neurofibromatosis (NF). Sponsored by the Children’s Tumor Foundation (www.ctf.org) and the Children’s Tumor Foundation Europe (www.ctfeurope.org), the NF Registry is a safe and effective tool to empower NF patients and their caregivers by inviting them to participate in relevant clinical trials and take an active role in advancing NF research.

The NF Registry is for all types of NF (including NF1, NF2, and schwannomatosis), and is open to all populations, including any age, race, ethnicity, or gender. NF knows no boundaries, and understanding its impact across all types of people from all over the world, from childhood to adulthood, is essential to finding the answers that will improve the lives of all NF patients.

NF Clinical Trials Consortium (NFCTC)

The NFCTC is dedicated to conducting clinical trials to improve the quality of life of persons with neurofibromatosis. Since the discovery of the genes responsible for the different forms of neurofibromatosis, much has been learned about how the various problems associated with neurofibromatosis come about. This opens the door towards development and testing of medications that may be helpful in preventing or treating complications of the disorders. The NF Clinical Trials Consortium was formed in 2006 with funding from the U.S. Army Medical Research and Materiel Command to carry out clinical trials of such medications. The Consortium consists of thirteen clinical centers with 12 around the U.S.; 1 in Australia, and an Operations Center at the University of Alabama Birmingham to coordinate consortium activities.

  • Boston/Harvard Center for NF & Allied Disorders
  • Children’s Hospital at Westmead, University of Sydney
  • Children’s Hospital Los Angeles
  • Children’s National Medical Center
  • Cincinnati Children’s Hospital Medical Center
  • Indiana University
  • Johns Hopkins Hospital
  • Massachusetts General Hospital
  • National Cancer Institute
  • New York University Medical Center
  • University of Alabama at Birmingham
  • University of Chicago
  • University of Pennsylvania
  • University of Utah
  • Washington University
  • Children’s Healthcare of Atlanta
  • Texas Scottish Rite Hospital
Consortium Members

NF Trials

ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Learn more about clinical studies and about this site, including relevant history, policies, and laws.

Search NF Clinical Trials

Antidote is a data-driven platform matching and searching more than 14,000 clinical trials in real-time.

Search Antidote